

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1<sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p><b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p><b>Kind Attn.:</b> Famroze Pochara Asst. Vice President</p>
<p><b>Date:</b> June 27, 2017</p>	
<p><b>Re.:</b> Press Release</p>	

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 27, 2017 titled "Zydus receives final approval from the USFDA for Entecavir Tablets."


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



**UPEN H. SHAH**  
**COMPANY SECRETARY**

**Encl.:** As above



## Zydus receives final approval from the USFDA for Entecavir Tablets

Ahmedabad, 27 June 2017

Zydus Cadila has received the final approval from the USFDA to market Entecavir Tablets in the strengths of 0.5 mg and 1 mg.

The drug is used in the treatment of Hepatitis B Virus infection and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The estimated sale for Entecavir tablets is \$ 166.3 million (*IMS MAT April 2017*).

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*